Framing Eighteen Coils in Cerebral Aneurysms Trial: FEAT
This trial is being conducted in order to compare angiographic outcomes in patients receiving 0.014-0.0155 platinum framing and filling coils (larger diameter coils) versus those treated solely with coils less than 0.014 (with a standard diameter). Hypothesis: Angiographic occlusion at follow-up imaging will be more frequent in patients receiving 0.014-0.0155 platinum coils during embolization compared to those receiving smaller-diameter coils.
• Patient presenting with ruptured or unruptured cerebral aneurysm appropriate for endovascular treatment as determined by the neurovascular treating team (neurointerventionist and/or neurosurgeon).
• The neurointerventionist feels that the aneurysm can be safely treated with either using, or not using, a 0.015-0.0155 platinum coil.
• Patients are 18-80 years of age (inclusive).
• Patient must be Hunt and Hess grade 0 to 3.
• Patient has given fully informed consent to endovascular coiling procedure. If the patient cannot consent for themselves, appropriate written consent has been sought from their next of kin or appropriate power of attorney.
• Aneurysm 6-14 mm in maximum diameter.
• Patient is willing and able to return for clinical evaluation and follow-up imaging evaluation (angiography or MRA) at 3-6 months and 12-18 months after endovascular treatment.
• The patient has not been previously randomized into this trial or another related ongoing trial.
• The aneurysm has not been previously treated by coiling or clipping.